Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00869544 · ClinicalTrials.gov registry record

Pneumocystis in Pathogenesis of HIV-associated Emphysema

A clinical trial, sponsored by University of Pittsburgh.

Completed
Registry status
250
Enrollment target

NCT00869544 is a clinical trial that has completed, run by University of Pittsburgh. The registered enrollment target is 250 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00869544 has completed, sponsored by University of Pittsburgh.

COMPLETED
Registry status
250 participants
Enrollment target

Study Summary

A. Statement of Hypotheses: HIV-infected patients have an increased incidence of emphysema compared to non-HIV-infected smokers, and it has been hypothesized that this accelerated disease progression is the result of one or more latent infections that amplifies the pulmonary inflammatory response to cigarette smoke. Pneumocystis is one infectious agent that likely plays a key role in the development of HIV-associated emphysema. Colonization with Pneumocystis has been demonstrated in HIV-infected subjects, and HIV-infected smokers are particularly susceptible to Pc colonization regardless of CD4 cell count or use of prophylaxis. Pneumocystis colonization is also increased in non-HIV-infected patients with chronic obstructive pulmonary disease (COPD) and is directly related to the severity of the disease. The presence of Pneumocystis in the lungs, even at low levels as seen in colonization, produces inflammatory changes similar to those seen in COPD, with increases in the numbers of neutrophils and cytotoxic CD8+ lymphocytes. We propose that Pneumocystis accelerates emphysema in HIV-infected smokers by stimulating inflammation and tissue destruction. We will examine the role of co-infection with Pneumocystis in the pathogenesis of HIV-associated emphysema and the mechanism by which it causes emphysema progression. These studies will lead to information that will provide a rational basis for prevention and therapy of HIV-associated emphysema and provide a model for emphysema in the general population

Trial Details

FieldValue
Enrollment Target 250 participants
Start Date 2007-08
Est. Completion 2013-07

Sponsor

University of Pittsburgh

1,238 total trials

What the Registry Record Tells You About NCT00869544

The ClinicalTrials.gov registry entry for NCT00869544 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 0 interventions.

NCT00869544 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00869544 about?

NCT00869544 is a clinical study titled "Pneumocystis in Pathogenesis of HIV-associated Emphysema". A. Statement of Hypotheses: HIV-infected patients have an increased incidence of emphysema compared to non-HIV-infected smokers, and it has been hypothesized that this accelerated disease progression is the result of one or more latent infections that amplifies the pulmonary inflammatory response t...

What is the current status of trial NCT00869544?

This trial is currently completed. The enrollment target is 250 participants. The study started on 2007-08. Estimated completion is 2013-07.

Who is sponsoring clinical trial NCT00869544?

This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.